Rochester, NY – December 10, 2012. Vaccinex, Inc. announced today that it presented information surrounding its antibody selection technology at the 2012 IBC Antibody Engineering and Antibody Therapeutics Conference in San Diego, CA from December 2nd through the 6th. Vaccinex’s antibody discovery platform uses a vaccinia virus-based library technology that enables efficient selection of fully functional IgG antibodies from highly diverse immunoglobulin gene libraries expressed on both viral particles and the membrane of the mammalian cells they infect. This novel approach rivals other commercial platforms in terms of throughput and diversity examined. Furthermore, it has the advantage of being a true mammalian cell-based platform that enriches for antibodies with favorable production profiles.
Click the following to review the poster from this conference;
Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies and other biologics to treat a variety of serious illnesses, including autoimmune disease, inflammation, multiple sclerosis, and cancer. The company’s patented ActivMAb® technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Vaccinex, on its own or with its partners, have developed antibodies from the discovery phase into three phase I clinical trials.